Ziprasidone hydrochloride suspension and preparation method thereof
By using specific combination ingredients and preparation methods in the oral suspension of ziprasidone hydrochloride, the stability and microbial problems of the oral suspension of ziprasidone hydrochloride were solved, and a good stable administration form was achieved, which simplified the Preparation process and improved quality control.
Patent Information
- Application Number
- CN202411100297.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-12
- Publication Date
- 2024-11-19
AI Technical Summary
The existing oral suspension preparation process of ziprasidone hydrochloride is complex and has poor physical stability, and has microbial problems, making it difficult to provide a stable drug delivery form.
Using a combination of ziprasidone hydrochloride, xanthan gum, colloidal silica, preservatives, flocculants, wetting agents and flavoring agents, ziprasidone hydrochloride with a particle size less than 50μm is prepared by a simple preparation method. Oral suspension, the process includes step-by-step mixing and stirring of the solution, leaving it to remove bubbles, and setting volume.
The oral suspension of ziprasidone hydrochloride has good stability, good taste, easy to adjust the administration, simple process and controllable quality, avoiding the occurrence of microbial problems.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The invention belongs to the field of pharmaceutical preparations and relates to a ziprasidone hydrochloride oral suspension and a preparation method thereof. Background Art
[0002] Ziprasidone is a psychotropic drug whose chemical composition is unrelated to phenothiazine or butanone antipsychotic drugs. It has a good effect on acute or chronic, initial or recurrent schizophrenia, and is effective for schizophrenia-related symptoms (including visual and auditory hallucinations, delusions, lack of motivation and social avoidance). Its molecular weight is 412.94 (free base), and its chemical name is as follows: 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one, and its chemical structure is as follows:
[0003] Ziprasidone hydrochloride oral suspension contains ziprasidone hydrochloride monohydrate. The chemical name of ziprasidone hydrochloride monohydrate is 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one monohydrochloride monohydrate. Its chemical formula is C21H21ClN4OS - HCl - H2O, and its molecular weight is 467.42. Ziprasidone hydrochloride monohydrate is a white to slightly pink powder.
[0004] Ziprasidone hydrochloride is the latest atypical broad-spectrum antipsychotic developed by Pfizer for the treatment of schizophrenia. This product is a 5-hydroxytryptamine and dopamine receptor antagonist, especially with strong affinity for 5-HT A2 / DA D2 receptors. The oral and intramuscular dosage forms of this drug were launched in Sweden in 1998 and September 2000, respectively. It has a good effect on acute or chronic, initial or recurrent schizophrenia; it is effective for schizophrenia-related symptoms (including visual and auditory hallucinations, delusions, lack of motivation and social avoidance). Compared with traditional antipsychotics, this drug can improve negative symptoms in addition to positive symptoms, improve cognitive function, greatly reduce adverse reactions, especially extrapyramidal symptoms, and significantly improve tolerance; compared with the widely used olanzapine, quetiapine, risperidone, etc., this product has better or equivalent efficacy on negative symptoms, does not cause weight gain and increase serum prolactin levels, and has fewer side effects than all existing atypical antipsychotics. This product is available in two dosage forms: injection and capsule, which can be used for acute / short-term and long-term treatment respectively.
[0005] Schizophrenia is a global public health problem. Schizophrenia typically develops in young adults and can cause lifelong disability. Schizophrenia is the most devastating disease affecting humans in terms of personal and financial costs. Schizophrenia affects approximately 1% of the world's population, with men and women equally affected. In the United States, schizophrenia accounts for 1 in 5 Social Security disability days and 2.5% of all health insurance costs. Schizophrenia is more common than Alzheimer's disease and multiple sclerosis. Because the symptoms of schizophrenia are unfamiliar, it is often difficult to pinpoint its onset, which can delay seeking medical attention for years. The average age of onset of schizophrenia is in the early 20s to mid-20s in men and slightly later in women. Childhood onset is rare, but schizophrenia can develop in adolescence and, rarely, in later life. The decline in social functioning can lead to substance use disorders, poverty, and homelessness. Untreated schizophrenia patients may become displaced because they lose touch with family and friends. This condition may last a lifetime, and in most cases leads to lifelong poor social functioning. The exact cause of schizophrenia is still unclear, but current research suggests that genetic and environmental factors play a role. However, it is essentially a biological problem (involving molecular and functional changes in the brain), but certain external factors (such as major life stress or substance use) can act as triggers. In recent years, the prevalence of mental illness in my country has continued to grow, with schizophrenia being the highest, with an estimated 8 million patients nationwide, and few antipsychotic drugs on the market. Ziprasidone has significant advantages in efficacy and side effects.
[0006] Compared with the inconvenience of oral capsules for children, elderly patients and patients with dysphagia, and the poor medication experience of injections, the ziprasidone hydrochloride oral suspension has good compliance and can be flexibly administered, making it more friendly to children and elderly patients.
[0007] Ziprasidone hydrochloride oral suspension is convenient for patients to individualize the dosing regimen, and the dosage is easy to adjust. However, the preparation process of oral suspension is generally relatively complicated, and the physical stability is poor during storage, and there are microbial problems common to liquid preparations. Therefore, how to provide a stable ziprasidone hydrochloride oral suspension and its preparation method is a key technical issue. Summary of the invention
[0008] The purpose of the present invention is to provide a ziprasidone hydrochloride oral suspension and a preparation method thereof in view of the problems mentioned in the technical background. The characteristics of the ziprasidone hydrochloride oral suspension are simple preparation process, good stability, easy for patients to take, and good taste.
[0009] The ziprasidone hydrochloride oral suspension provided by the present invention comprises ziprasidone hydrochloride, xanthan gum, colloidal silicon dioxide, a preservative, and a flocculant; Furthermore, in the ziprasidone hydrochloride oral suspension, the ziprasidone hydrochloride is a monohydrate; the xanthan gum uses a type other than 11K, which can be purchased from CP Kelco Okmulgee plant; the colloidal silica is hydrophilic colloidal silica; the preservative is one or more of methylparaben, propylparaben, sorbic acid and potassium sorbate; the flocculant is one or more of citric acid, sodium citrate, sodium chloride, disodium hydrogen phosphate and sodium dihydrogen phosphate; Furthermore, the ziprasidone hydrochloride oral suspension further comprises a wetting agent selected from one or more of polysorbate 80, sodium lauryl sulfate and polyoxyethylene stearate; Furthermore, the ziprasidone hydrochloride oral suspension further comprises a flavoring agent selected from one or more of xylitol, sorbitol, saccharin sodium, cherry flavor, strawberry flavor and sweet orange flavor; The ziprasidone hydrochloride oral suspension provided by the present invention has the following prescription composition and dosage:
[0010] Furthermore, the ziprasidone hydrochloride oral suspension is characterized in that the particle size of the ziprasidone hydrochloride oral suspension is less than 50 μm; Furthermore, the method for preparing the ziprasidone hydrochloride oral suspension is characterized by comprising the following steps: (1) Stir and dissolve the wetting agent in an appropriate amount of purified water to prepare solution A; (2) Heat and stir the preservative in an appropriate amount of purified water to dissolve it, and add it to solution A while it is hot to obtain solution B; (3) Add, flocculant, and sweetener to an appropriate amount of purified water in sequence, stirring and dissolving to obtain solution C; (4) Add a suspending agent to an appropriate amount of purified water and stir to mix evenly, then add solution B and solution C in sequence and mix evenly, add ziprasidone hydrochloride and stir vigorously to make it evenly dispersed in the solution; (5) Allow to stand to remove air bubbles and adjust the volume.
[0011] Example 1
[0012] Preparation process (1) Stir and dissolve the wetting agent in an appropriate amount of purified water to prepare solution A; (2) Heat and stir the preservative in an appropriate amount of purified water to dissolve it, and add it to solution A while it is hot to obtain solution B; (3) Add, flocculant, and sweetener to an appropriate amount of purified water in sequence, stirring and dissolving to obtain solution C; (4) Add a suspending agent to an appropriate amount of purified water and stir to mix evenly, then add solution B and solution C in sequence and mix evenly, add ziprasidone hydrochloride and stir vigorously to make it evenly dispersed in the solution; (5) Allow to stand to remove air bubbles and adjust the volume.
[0013] Example 2
[0014] Preparation process (1) Stir and dissolve the wetting agent in an appropriate amount of purified water to prepare solution A; (2) Heat and stir the preservative in an appropriate amount of purified water to dissolve it, and add it to solution A while it is hot to obtain solution B; (3) Add, flocculant, and sweetener to an appropriate amount of purified water in sequence, stirring and dissolving to obtain solution C; (4) Add a suspending agent to an appropriate amount of purified water and stir to mix evenly, then add solution B and solution C in sequence and mix evenly, add ziprasidone hydrochloride and stir vigorously to make it evenly dispersed in the solution; (5) Allow to stand to remove air bubbles and adjust the volume.
[0015] Example 3
[0016] Preparation process Add simethicone, polyoxyethylene stearate and polyvinyl alcohol (1) in sequence to an appropriate amount of purified water, stir and dissolve the wetting agent in an appropriate amount of purified water to prepare solution A; (2) Heat and stir the preservative in an appropriate amount of purified water to dissolve it, and add it to solution A while it is hot to obtain solution B; (3) Add, flocculant, and sweetener to an appropriate amount of purified water in sequence, stirring and dissolving to obtain solution C; (4) Add a suspending agent to an appropriate amount of purified water and stir to mix evenly, then add solution B and solution C in sequence and mix evenly, add ziprasidone hydrochloride and stir vigorously to make it evenly dispersed in the solution; (5) Allow to stand to remove air bubbles and adjust the volume.
[0017] Example 4
[0018] Preparation process (1) Stir and dissolve the wetting agent in an appropriate amount of purified water to prepare solution A; (2) Heat and stir the preservative in an appropriate amount of purified water to dissolve it, and add it to solution A while it is hot to obtain solution B; (3) Add, flocculant, and sweetener to an appropriate amount of purified water in sequence, stirring and dissolving to obtain solution C; (4) Add a suspending agent to an appropriate amount of purified water and stir to mix evenly, then add solution B and solution C in sequence and mix evenly, add ziprasidone hydrochloride and stir vigorously to make it evenly dispersed in the solution; (5) Allow to stand to remove air bubbles and adjust the volume.
[0019] Example 5
[0020] Preparation process (1) Stir and dissolve the wetting agent in an appropriate amount of purified water to prepare solution A; (2) Heat and stir the preservative in an appropriate amount of purified water to dissolve it, and add it to solution A while it is hot to obtain solution B; (3) Add, flocculant, and sweetener to an appropriate amount of purified water in sequence, stirring and dissolving to obtain solution C; (4) Add a suspending agent to an appropriate amount of purified water and stir to mix evenly, then add solution B and solution C in sequence and mix evenly, add ziprasidone hydrochloride and stir vigorously to make it evenly dispersed in the solution; (5) Allow to stand to remove air bubbles and adjust the volume.
[0021] Comparative Example 1
[0022] Preparation process (1) Stir and dissolve the wetting agent in an appropriate amount of purified water to prepare solution A; (2) Heat and stir the preservative in an appropriate amount of purified water to dissolve it, and add it to solution A while it is hot to obtain solution B; (3) Add, flocculant, and sweetener to an appropriate amount of purified water in sequence, stirring and dissolving to obtain solution C; (4) Add a suspending agent to an appropriate amount of purified water and stir to mix evenly, then add solution B and solution C in sequence and mix evenly, add ziprasidone hydrochloride and stir vigorously to make it evenly dispersed in the solution; (5) Allow to stand to remove air bubbles and adjust the volume.
[0023] Comparative Example 2
[0024] Preparation process (1) Stir and dissolve the wetting agent in an appropriate amount of purified water to prepare solution A; (2) Heat and stir the preservative in an appropriate amount of purified water to dissolve it, and add it to solution A while it is hot to obtain solution B; (3) Add, flocculant, and sweetener to an appropriate amount of purified water in sequence, stirring and dissolving to obtain solution C; (4) Add a suspending agent to an appropriate amount of purified water and stir to mix evenly, then add solution B and solution C in sequence and mix evenly, add ziprasidone hydrochloride and stir vigorously to make it evenly dispersed in the solution; (5) Allow to stand to remove air bubbles and adjust the volume.
[0025] Comparative Example 3
[0026] Preparation process (1) Stir and dissolve the wetting agent in an appropriate amount of purified water to prepare solution A; (2) Heat and stir the preservative in an appropriate amount of purified water to dissolve it, and add it to solution A while it is hot to obtain solution B; (3) Add, flocculant, and sweetener to an appropriate amount of purified water in sequence, stirring and dissolving to obtain solution C; (4) Add a suspending agent to an appropriate amount of purified water and stir to mix evenly, then add solution B and solution C in sequence and mix evenly, add ziprasidone hydrochloride and stir vigorously to make it evenly dispersed in the solution; (5) Allow to stand to remove air bubbles and adjust the volume.
[0027] According to the pharmacopoeia standards and methods, the key quality attributes, related substances and contents of Examples 1-5 and Comparative Examples 1-3 were investigated, and a preliminary investigation of their stability was conducted. The results are as follows:
[0028]
[0029]
[0030] As can be seen from the above table, the growth trend of the related substances in Examples 1-5 is good, the content has not changed significantly, the stability is good, the sample quality has basically not changed, and the preparation process is simple and the quality is controllable. However, the content of Comparative Examples 1-3 has changed greatly, the content of the main component is uneven; the sedimentation volume ratio of Comparative Example 3 is unqualified; the related substances in Comparative Examples 1 and 2 are larger, and the related substances in Comparative Examples 1 and 2 have increased significantly under accelerated conditions.
[0031] In summary, the ziprasidone hydrochloride oral suspension of the present invention has stable process, qualified content and good quality.
[0032] The above embodiments are intended to illustrate the present invention, not to limit the present invention. Any solution that is a simple transformation of the present invention belongs to the protection scope of the present invention.
Claims
1. A ziprasidone hydrochloride oral suspension comprising ziprasidone hydrochloride, xanthan gum, colloidal silicon dioxide, a preservative and a flocculant.
2. The ziprasidone hydrochloride oral suspension according to claim 1, wherein the ziprasidone hydrochloride is a monohydrate; the xanthan gum uses a type other than 11K, which can be purchased from CP Kelco Okmulgee plant; the colloidal silica is hydrophilic colloidal silica; the preservative is one or more of methylparaben, propylparaben, sorbic acid and potassium sorbate; and the flocculant is one or more of citric acid, sodium citrate, sodium chloride, disodium hydrogen phosphate and sodium dihydrogen phosphate.
3. The ziprasidone hydrochloride oral suspension according to claim 1, comprising 5-15 mg / ml of ziprasidone hydrochloride monohydrate, 2.5-6.0 mg / ml of a suspending agent, 1.5-2.5 mg / ml of a preservative, and 0.5-7.5 mg / ml of a flocculant.
4. The ziprasidone hydrochloride oral suspension according to claims 1-3, further comprising a wetting agent selected from one or more of polysorbate 80, sodium lauryl sulfate and polyoxyethylene stearate.
5. The ziprasidone hydrochloride oral suspension according to claims 1-4, further comprising a flavoring agent selected from one or more of xylitol, sorbitol, saccharin sodium, cherry flavor, strawberry flavor and sweet orange flavor.
6. The ziprasidone hydrochloride oral suspension according to claims 1-5, characterized in that: The particle size D90 of the ziprasidone hydrochloride oral suspension is less than 50 μm.
7. A method for preparing ziprasidone hydrochloride oral suspension, characterized in that: The following steps are involved: (1) Stir and dissolve the wetting agent in an appropriate amount of purified water to prepare solution A; (2) Heat and stir the preservative in an appropriate amount of purified water to dissolve it, and add it to solution A while it is hot to obtain solution B; (3) Add, flocculant, and sweetener to an appropriate amount of purified water in sequence, stirring and dissolving to obtain solution C; (4) Add a suspending agent to an appropriate amount of purified water and stir to mix evenly, then add solution B and solution C in sequence and mix evenly, add ziprasidone hydrochloride and stir vigorously to make it evenly dispersed in the solution; Let stand to remove bubbles and adjust volume.
